Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07554846 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC

Study acronym: ECTOP-1030
StatusRecruiting
PhasePhase 3
Started2026-05-01
View on ClinicalTrials.gov ↗

Amendment history

2026-09-06
Study Status, Study Description, Eligibility, Contacts/Locations v1
Recruitment opened
Eligibility criteria-4 characters
[...] small cell lung cancer (according to the AJCC 8th edition), without EGFR wild type, and no /ALK rearrangementsensitive mutations, confirmed by histology or pathology; ECOG PS score of 0-1; [...]
Study sitesdetails revised at 1 of 1 site
2026-04-21
Original filing
This is a randomized, open-label, multi-center Phase III clinical study aimed at head-to-head evaluating the clinical efficacy of three immunotherapy strategies, namely perioperative immunotherapy, neoadjuvant immunotherapy, and adjuvant immunotherapy using Toripalimab, in patients with resectable stage II-IIIA non-small cell lung cancer (NSCLC) without EGFR/ALK sensitive mutations. This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1030.
Trial Details
NCT Number NCT07554846
Lead Sponsor Fudan University
Conditions Resectable Stage II-IIIa NSCLC
Enrollment 759 participants
Start Date 2026-05-01
Primary Completion 2030-05-01 (estimated)
Study Completion 2032-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-10